Summer 2011

Early detection offers the best chance for a cure.

You'd never know that Rogers has had multiple myeloma for almost 11 years -- and that's just the way he likes it.

Progress in our understanding of multiple myeloma pathogenesis has led to the identification of new therapeutic targets.

It is estimated that approximately 80% of all patients with diagnoses of breast cancer, prostate cancer, or multiple myeloma will develop bone metastases at some time during the course of their disease.

Diffuse large B-cell non-Hodgkin lymphoma is typically a chemotherapy-sensitive malignancy, justifying dose-intense therapy with hematopoietic stem cell transplantation for patients unlikely to achieve cure with standard-dose regimens.

A look at dramatic changes in the landscape of multiple myeloma that have occurred over the past decade and new developments in the context of stem cell transplantation in non-Hodgkin lymphoma.